Medicare Enrolled
Dr. Thomas Harder, M.D.
Rheumatology · Wynnewood, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Harder from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harder?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harder
Dr. Thomas Harder is a rheumatology specialist in Wynnewood, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Harder performed 51,159 Medicare services across 1,639 unique beneficiaries.
Between the years covered by Open Payments, Dr. Harder received a total of $23,299 from 60 pharmaceutical and/or device companies across 1295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harder is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 22% volume in PA
$23,299 industry payments
Medicare Practice Summary
Medicare Utilization ↗51,159
Medicare services
Top 22% in PA for rheumatology
1,639
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~2,558 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
31,200 | $4 | $10 |
| Denosumab injection (Prolia/Xgeva) | 16,680 | $18 | $40 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
974 | $96 | $217 |
| Injection, methylprednisolone acetate, 40 mg | 409 | $6 | $20 |
| Joint injection, major joint Removal of fluid from a large joint and/or injection of medication into the joint space. |
358 | $54 | $131 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
291 | $11 | $50 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
250 | $1 | $11 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
198 | $64 | $146 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
154 | $104 | $322 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
153 | $60 | $184 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
133 | $1 | $25 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
120 | $5 | $113 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
84 | $131 | $253 |
| Joint fluid aspiration or injection, medium joint Removal of fluid from a medium-sized joint or injection of medication into the joint space. |
38 | $39 | $92 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
38 | $144 | $272 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
28 | $46 | $170 |
| Joint fluid aspiration or injection, small joint Removal of fluid from a small joint or injection of medication into a small joint. |
26 | $39 | $100 |
| Trigger point injection, 1-2 muscles A procedure involving the injection of medication into one or two specific muscles to treat trigger points. |
25 | $41 | $85 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.6% high complexity
96.9% medium
2.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$23,299
Total received (2018-2024)
Avg $3,328/year across 7 years
Top 17% in PA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
60
Companies
1,295
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$23,214 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$85 (0.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,912
2023
$3,637
2022
$3,118
2021
$2,275
2020
$2,737
2019
$3,803
2018
$3,817
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$792
ABBVIE INC.
$514
AstraZeneca Pharmaceuticals LP
$482
UCB, Inc.
$476
E.R. Squibb & Sons, L.L.C.
$202
Radius Health, Inc.
$195
Lilly USA, LLC
$192
Novartis Pharmaceuticals Corporation
$140
Collegium Pharmaceutical, Inc.
$104
PFIZER INC.
$89
Boehringer Ingelheim Pharmaceuticals, Inc.
$89
Almatica Pharma LLC
$76
Mallinckrodt Hospital Products Inc.
$74
GlaxoSmithKline, LLC.
$71
Alexion Pharmaceuticals, Inc.
$53
Kiniksa Pharmaceuticals International, plc
$50
Aurinia Pharma U.S., Inc.
$47
Genentech USA, Inc.
$46
Organon Llc
$30
Zimmer Biomet Holdings, Inc.
$28
Ultragenyx Pharmaceutical Inc.
$23
Invivyd Inc
$23
Sandoz Inc.
$19
Janssen Biotech, Inc.
$18
Kyowa Kirin, Inc.
$17
Fresenius Kabi USA, LLC
$16
ANI Pharmaceuticals, Inc.
$16
Novo Nordisk Inc
$16
GENZYME CORPORATION
$14
Top 3 companies account for 45.7% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$4,157
ABBVIE INC.
$1,680
UCB, Inc.
$1,618
AstraZeneca Pharmaceuticals LP
$1,557
PFIZER INC.
$1,452
Novartis Pharmaceuticals Corporation
$1,313
AbbVie, Inc.
$1,172
E.R. Squibb & Sons, L.L.C.
$1,133
Janssen Biotech, Inc.
$1,119
Radius Health, Inc.
$758
Lilly USA, LLC
$747
Genentech USA, Inc.
$697
GlaxoSmithKline, LLC.
$663
AbbVie Inc.
$599
GENZYME CORPORATION
$527
Horizon Therapeutics plc
$373
Boehringer Ingelheim Pharmaceuticals, Inc.
$372
Mallinckrodt Hospital Products Inc.
$315
Aurinia Pharma U.S., Inc.
$307
Celgene Corporation
$247
Mallinckrodt Enterprises LLC
$211
Sobi, Inc
$154
Flexion Therapeutics, Inc.
$144
Alexion Pharmaceuticals, Inc.
$143
Collegium Pharmaceutical, Inc.
$139
ANI Pharmaceuticals, Inc.
$129
Kiniksa Pharmaceuticals, Ltd.
$117
Mallinckrodt LLC
$114
Kyowa Kirin, Inc.
$98
DePuy Synthes Sales Inc.
$92
Almatica Pharma LLC
$76
Hikma Pharmaceuticals USA
$72
Actelion Pharmaceuticals US, Inc.
$72
SOBI, INC
$71
MEDEXUS PHARMA, INC.
$64
Exeltis, USA Inc.
$58
Antares Pharma, Inc.
$55
Sandoz Inc.
$55
Kiniksa Pharmaceuticals International, plc
$50
Kowa Pharmaceuticals America, Inc.
$46
Novo Nordisk Inc
$40
Horizon Pharma plc
$40
MEDAC PHARMA, INC.
$39
Ultragenyx Pharmaceutical Inc.
$39
Takeda Pharmaceuticals U.S.A., Inc.
$36
Bioventus LLC
$35
Fresenius Kabi USA, LLC
$35
Organon LLC
$32
SANOFI-AVENTIS U.S. LLC
$31
Organon Llc
$30
Zimmer Biomet Holdings, Inc.
$28
Merck Sharp & Dohme Corporation
$26
Invivyd Inc
$23
Iroko Pharmaceuticals, LLC
$16
Ferring Pharmaceuticals Inc.
$15
Celltrion USA Inc.
$15
Purdue Pharma L.P.
$15
Mission Pharmacal Company
$14
Orthogenrx Inc.
$12
Sebela Pharmaceuticals Inc.
$12
Top 3 companies account for 32.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · Aquoral · Arcalyst · BENLYSTA · Belbuca · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · EUFLEXXA · EVENITY · EVUSHELD · Enbrel · FORTEO · GELSYN 3 · Gel-One Cross-linked Hyaluronate · GenVisc 850 · HADLIMA · HUMIRA · HYRIMOZ · Humira · IDACIO · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · MONOVISC · Mitigare · NUCALA · OFEV · ORENCIA · ORTHOVISC · OXYCONTIN · Otezla · Otrexup · PEMGARDA · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · RHEUMATOID ARTHRITIS DISEASE · RIDAURA · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · SYNVISC-ONE · Seglentis · Sodium Chloride · Strensiq · TALTZ · TAVNEOS · TERIPARATIDE · TREMFYA · Tavneos · Tymlos · UPTRAVI · Uloric · VIVLODEX · Wegovy · XELJANZ · XTAMPZA · YUFLYMA · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Rheumatologists within 10 mi
175
Per 100K population
20.3
County median income
$111,521
Nearest hospital
MAIN LINE HOSPITAL LANKENAU
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Harder is a mixed practice specialist, with above-average Medicare volume (top 22% in PA), with low-engagement industry engagement in the top 17% of PA peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Harder experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Harder performed 31,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harder receive payments from pharmaceutical companies?
Yes. Dr. Harder received a total of $23,299 from 60 companies across 1,295 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harder's costs compare to other rheumatologists in Wynnewood?
Dr. Harder's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harder) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Wynnewood
Browse rheumatologists in Wynnewood ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in PA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in PA
Which PA rheumatologists receive the most from drug and device companies.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology